249 related articles for article (PubMed ID: 34958539)
1. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
4. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Kao WY; Tan EC; Lee HL; Huang YH; Huo TI; Chang CC; Chiou JF; Hou MC; Wu JC; Su CW
Aliment Pharmacol Ther; 2023 Jun; 57(11):1299-1312. PubMed ID: 36914943
[TBL] [Abstract][Full Text] [Related]
5. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
Linye H; Zijing X; Xiaoyun Z; Zhihui L; Tianfu W; Chuan L
Int J Surg; 2023 Oct; 109(10):3032-3041. PubMed ID: 37335984
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
[TBL] [Abstract][Full Text] [Related]
11. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
Peng W; Yi M; Qi X; Qi W; Li C; Wen T
Trials; 2023 Dec; 24(1):781. PubMed ID: 38042834
[TBL] [Abstract][Full Text] [Related]
12. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
[TBL] [Abstract][Full Text] [Related]
13. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
14. Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
Kim DG; Choi Y; Rhu J; Hwang S; You YK; Kim DS; Nah YW; Kim BW; Cho JY; Kang KJ; Yang JD; Choi D; Joo DJ; Kim MS; Ryu JH; Lee JG;
Liver Transpl; 2023 Dec; 29(12):1272-1281. PubMed ID: 37489922
[TBL] [Abstract][Full Text] [Related]
15. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
[TBL] [Abstract][Full Text] [Related]
16. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation.
Yang J; Chen Y; Sun H; Zhang X; Wang J; Liang Z; Fu B; Zhang T; Yi S; Deng Y; Yang Y
Infect Agent Cancer; 2023 Jan; 18(1):2. PubMed ID: 36650583
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
[TBL] [Abstract][Full Text] [Related]
19. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Su F; Berry K; Ioannou GN
Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
